Reduction of Th17+ Lymphocytes in patients with SAPHO syndrome and psoriatic arthritis before and under treatment with secukinumab.

Trial Profile

Reduction of Th17+ Lymphocytes in patients with SAPHO syndrome and psoriatic arthritis before and under treatment with secukinumab.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Acquired hyperostosis syndrome; Psoriatic arthritis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top